Neuronetics Announces That Additional Payors Have Updated Their TMS Coverage To Reduce Access Barriers For Patients With Major Depressive Disorder
Neuronetics Announces That Additional Payors Have Updated Their TMS Coverage To Reduce Access Barriers For Patients With Major Depressive Disorder
Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that additional payors have updated their TMS (transcranial magnetic stimulation) coverage to reduce access barriers for patients with major depressive disorder (MDD). This expanded access allows people to receive treatment such as the Company's NeuroStar TMS Therapy earlier in their treatment regimen.
納斯達克：適應主要抑鬱障礙 (MDD) 病人的神經健康障礙，Neuronetics, Inc. (納斯達克：STIM)，一家專注於設計、開發和銷售改善患者生活質量的醫療技術公司，宣佈其他支付人已更新他們的TMS (經顱磁刺激) 覆蓋範圍，以減少主要抑鬱障礙 (MDD) 病人的就醫障礙。這種擴大的覆蓋範圍使人們能夠在他們的治療計劃早期接受像公司的NeuroStar TMS療法這樣的治療。
Effective immediately, BlueCross BlueShield (BCBS) of North Carolina has expanded its TMS policy to cover adolescents 15 years and older, based on recent clearance from the United States Food and Drug Administration (FDA) for NeuroStar as the first and only TMS treatment authorized for this population. BCBC of North Carolina policies affect more than 2.2 million covered lives. Additionally, Louisiana Medicaid has started covering TMS for adults 18 and older, effective immediately. This is the first TMS coverage policy from Louisiana Medicaid, which has a footprint of more than 1.6 million covered lives.
北卡羅來納州BlueCross BlueShield（BCBS）的TMS政策已立即擴大覆蓋範圍，針對15歲及以上的青少年，根據美國食品和藥物管理局（FDA）對NeuroStar作爲首個並且唯一的TMS治療適用於該人群的最新審批。北卡羅來納州的BCBC政策影響超過220萬的被保人。此外，路易斯安那州醫療補助已經開始覆蓋18歲及以上的成年人的TMS治療，立即生效。這是路易斯安那州醫療補助的首個TMS覆蓋政策，影響超過160萬的被保人。
譯文內容由第三人軟體翻譯。
